Suppression of kaposi's sarcoma-associated herpesvirus infection and replication by 5'-AMP-activated protein kinase

Journal of Virology

Volumn 90, Issue 14, 2016, Pages 6515-6525

  Cheng, Fan ^a   He, Meilan ^a   Jung, Jae U ^a   Lu, Chun ^b   Gao, Shou Jiang ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 5' AMP ACTIVATED PROTEIN KINASE; 5' AMP ACTIVATED PROTEIN KINASE ALPHA 1; 5' AMP ACTIVATED PROTEIN KINASE ALPHA 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LANA PROTEIN; METFORMIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; ANTIDIABETIC AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; KAPOSI SARCOMA; KAPOSI SARCOMA ASSOCIATED HERPESVIRUS INFECTION; LANA GENE; MOLECULAR DOCKING; OFF LABEL DRUG USE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; UMBILICAL VEIN ENDOTHELIAL CELL; VIRION; VIRUS GENE; VIRUS INHIBITION; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; HUMAN HERPESVIRUS 8; METABOLISM; PHOSPHORYLATION; SARCOMA, KAPOSI; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY;

AMP-ACTIVATED PROTEIN KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HERPESVIRUS 8, HUMAN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PHOSPHORYLATION; SARCOMA, KAPOSI; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84977524716     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00624-16     Document Type: Article

References (54)

1. Johnson WE. 2013. Rapid adversarial co-evolution of viruses and cellular restriction factors. Curr Top Microbiol Immunol 371:123-151. http://dx .doi.org/10.1007/978-3-642-37765-5_5.
2. Goubau D, Deddouche S, Reis e Sousa C. 2013. Cytosolic sensing of viruses. Immunity 38:855-869. http://dx.doi.org/10.1016/j.immuni.2013 .05.007.
3. Simon V, Bloch N, Landau NR. 2015. Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat Immunol 16:546-553. http://dx.doi .org/10.1038/ni.3156.
4. Zhou LY, Zhang LL. 2016. Host restriction factors for hepatitis C virus. World J Gastroenterol 22:1477-1486. http://dx.doi.org/10.3748/wjg.v22 .i4.1477.
5. Mihaylova MM, Shaw RJ. 2011. The AMPK signalling pathway coordi-nates cell growth, autophagy and metabolism. Nat Cell Biol 13:1016- 1023. http://dx.doi.org/10.1038/ncb2329.
6. Hardie DG, Ross FA, Hawley SA. 2012. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13:251- 262. http://dx.doi.org/10.1038/nrm3311.
7. Crozet P, Margalha L, Confraria A, Rodrigues A, Martinho C, Adamo M, Elias CA, Baena-Gonzalez E. 2014. Mechanisms of regulation of SNF1/AMPK/SnRK1 protein kinases. Front Plant Sci 5:190. http://dx.doi .org/10.3389/fpls.2014.00190.
8. Inoki K, Kim J, Guan KL. 2012. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 52:381-400. http://dx.doi.org/10.1146/annurev-pharmtox-010611-134537.
9. Mair W, Morantte I, Rodrigues AP, Manning G, Montminy M, Shaw RJ, Dillin A. 2011. Lifespan extension induced by AMPK and calcineurin is mediated by CRTC-1 and CREB. Nature 470:404-408. http://dx.doi .org/10.1038/nature09706.
10. Motoshima H, Goldstein BJ, Igata M, Araki E. 2006. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574:63-71. http://dx.doi.org/10.1113/jphysiol.2006.108324.
11. Momcilovic M, Hong SP, Carlson M. 2006. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem 281:25336-25343. http://dx.doi.org/10.1074 /jbc.M604399200.
12. Mankouri J, Harris M. 2011. Viruses and the fuel sensor: the emerging link between AMPK and virus replication. Rev Med Virol 21:205-212. http://dx.doi.org/10.1002/rmv.687.
13. Moser TS, Schieffer D, Cherry S. 2012. AMP-activated kinase restricts Rift Valley fever virus infection by inhibiting fatty acid synthesis. PLoS Pathog 8:e1002661. http://dx.doi.org/10.1371/journal.ppat.1002661.
14. Kondratowicz AS, Hunt CL, Davey RA, Cherry S, Maury WJ. 2013. AMP-activated protein kinase is required for the macropinocytic internalization of ebolavirus. J Virol 87:746-755. http://dx.doi.org/10.1128/JVI .01634-12.
15. Moser TS, Jones RG, Thompson CB, Coyne CB, Cherry S. 2010. A kinome RNAi screen identified AMPK as promoting poxvirus entry through the control of actin dynamics. PLoS Pathog 6:e1000954. http://dx .doi.org/10.1371/journal.ppat.1000954.
16. Terry LJ, Vastag L, Rabinowitz JD, Shenk T. 2012. Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection. Proc Natl Acad SciUSA109:3071- 3076. http://dx.doi.org/10.1073/pnas.1200494109.
17. Leyton L, Hott M, Acuna F, Caroca J, Nunez M, Martin C, Zambrano A, Concha MI, Otth C. 2015. Nutraceutical activators of AMPK/Sirt1 axis inhibit viral production and protect neurons from neurodegenerative events triggered during HSV-1 infection. Virus Res 205:63-72. http://dx .doi.org/10.1016/j.virusres.2015.05.015.
18. Hutterer C, Wandinger SK, Wagner S, Muller R, Stamminger T, Zeittrager I, Godl K, Baumgartner R, Strobl S, Marschall M. 2013. Profiling of the kinome of cytomegalovirus-infected cells reveals the functional importance of host kinases Aurora A, ABL and AMPK. Antiviral Res 99:139-148. http://dx.doi.org/10.1016/j.antiviral.2013.04.017.
19. Martin C, Leyton L, Arancibia Y, Cuevas A, Zambrano A, Concha MI, Otth C. 2014. Modulation of the AMPK/Sirt1 axis during neuronal infection by herpes simplex virus type 1. J Alzheimers Dis 42:301-312. http://dx .doi.org/10.3233/JAD-140237.
20. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869. http://dx.doi .org/10.1126/science.7997879.
21. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332:1186-1191. http://dx .doi.org/10.1056/NEJM199505043321802.
22. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d'Agay MF, Clauvel JP, Raphael M, Degos L, Sigaux F. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86:1276-1280.
23. Wang L, Damania B. 2008. Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells. Cancer Res 68:4640- 4648. http://dx.doi.org/10.1158/0008-5472.CAN-07-5988.
24. Gao SJ, Deng JH, Zhou FC. 2003. Productive lytic replication of a recombinant Kaposi's sarcoma-associated herpesvirus in efficient primary infection of primary human endothelial cells. J Virol 77:9738-9749. http://dx.doi.org/10.1128/JVI.77.18.9738-9749.2003.
25. Zhao Q, Liang D, Sun R, Jia B, Xia T, Xiao H, Lan K. 2015. Kaposi's sarcoma-associated herpesvirus-encoded replication and transcription activator impairs innate immunity via ubiquitin-mediated degradation of myeloid differentiation factor 88. J Virol 89:415-427. http://dx.doi.org/10 .1128/JVI.02591-14.
26. Brulois KF, Chang H, Lee AS, Ensser A, Wong LY, Toth Z, Lee SH, Lee HR, Myoung J, Ganem D, Oh TK, Kim JF, Gao SJ, Jung JU. 2012. Construction and manipulation of a new Kaposi's sarcoma-associated herpesvirus bacterial artificial chromosome clone. J Virol 86:9708-9720. http://dx.doi.org/10.1128/JVI.01019-12.
27. Zhou FC, Zhang YJ, Deng JH, Wang XP, Pan HY, Hettler E, Gao SJ. 2002. Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J Virol 76:6185-6196. http://dx.doi.org/10.1128/JVI.76 .12.6185-6196.2002.
28. Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, Ziegler J, Newton R, Rinaldo CR, Saah A, Phair J, Detels R, Chang Y, Moore PS. 1996. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 2:925-928. http://dx.doi.org/10 .1038/nm0896-925.
29. Greene W, Zhang W, He M, Witt C, Ye F, Gao SJ. 2012. The ubiquitin/ proteasome system mediates entry and endosomal trafficking of Kaposi's sarcoma-associated herpesvirus in endothelial cells. PLoS Pathog 8:e1002703. http://dx.doi.org/10.1371/journal.ppat.1002703.
30. Yoo SM, Zhou FC, Ye FC, Pan HY, Gao SJ. 2005. Early and sustained expression of latent and host modulating genes in coordinated transcriptional program of KSHV productive primary infection of human primary endothelial cells. Virology 343:47-64. http://dx.doi.org/10.1016/j.virol .2005.08.018.
31. Cheng F, Sawant TV, Lan K, Lu C, Jung JU, Gao SJ. 2015. Screening of the human kinome identifies MSK1/2-CREB1 as an essential pathway mediating Kaposi's sarcoma-associated herpesvirus lytic replication during primary infection. J Virol 89:9262-9280. http://dx.doi.org/10.1128/JVI .01098-15.
32. He M, Zhang W, Bakken T, Schutten M, Toth Z, Jung JU, Gill P, Cannon M, Gao SJ. 2012. Cancer angiogenesis induced by Kaposi's sarcoma- associated herpesvirus is mediated by EZH2. Cancer Res 72:3582- 3592. http://dx.doi.org/10.1158/0008-5472.CAN-11-2876.
33. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane-Kishikawa T, Hill DE, Vidal M, Meyerson M, Grenier JK, Hinkle G, Root DE, Roberts TM, Lander ES, Polyak K, Hahn WC. 2007. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129:1065-1079. http://dx .doi.org/10.1016/j.cell.2007.03.052.
34. Greene W, Gao SJ. 2009. Actin dynamics regulate multiple endosomal steps during Kaposi's sarcoma-associated herpesvirus entry and trafficking in endothelial cells. PLoS Pathog 5:e1000512. http://dx.doi.org/10 .1371/journal.ppat.1000512.
35. Park SH, Gammon SR, Knippers JD, Paulsen SR, Rubink DS, Winder WW. 2002. Phosphorylation-activity relationships of AMPK and acetyl- CoA carboxylase in muscle. J Appl Physiol (1985) 92:2475-2482. http://dx .doi.org/10.1152/japplphysiol.00071.2002.
36. Stapleton D, Mitchelhill KI, Gao G, Widmer J, Michell BJ, Teh T, House CM, Fernandez CS, Cox T, Witters LA, Kemp BE. 1996. Mammalian AMP-activated protein kinase subfamily. J Biol Chem 271:611- 614. http://dx.doi.org/10.1074/jbc.271.2.611.
37. Zhang W, Gao SJ. 2012. Exploitation of cellular cytoskeletons and signaling pathways for cell entry by Kaposi's sarcoma-associated herpesvirus and the closely related rhesus rhadinovirus. Pathogens 1:102-127. http: //dx.doi.org/10.3390/pathogens1020102.
38. Ye F, Lei X, Gao SJ. 2011. Mechanisms of Kaposi's sarcoma-associated herpesvirus latency and reactivation. Adv Virol 2011:193860.
39. Greene W, Kuhne K, Ye F, Chen J, Zhou F, Lei X, Gao SJ. 2007. Molecular biology of KSHV in relation to AIDS-associated oncogenesis. Cancer Treat Res 133:69 -127. http://dx.doi.org/10.1007/978-0 -387-46816-7_3.
40. Crute BE, Seefeld K, Gamble J, Kemp BE, Witters LA. 1998. Functional domains of the alpha1 catalytic subunit of the AMP-activated protein kinase. J Biol Chem 273:35347-35354. http://dx.doi.org/10.1074/jbc.273 .52.35347.
41. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. 2007. The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297-315. http: //dx.doi.org/10.1042/BJ20070797.
42. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 1995. 5-aminoimidazole- 4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229:558-565.
43. Pold R, Jensen LS, Jessen N, Buhl ES, Schmitz O, Flyvbjerg A, Fujii N, Goodyear LJ, Gotfredsen CF, Brand CL, Lund S. 2005. Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes 54:928-934. http://dx.doi.org/10.2337/diabetes.54.4.928.
44. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174. http://dx.doi.org/10.1172 /JCI13505.
45. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear LJ. 2002. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51:2074-2081. http://dx.doi.org/10.2337/diabetes.51.7.2074.
46. Akula SM, Naranatt PP, Walia NS, Wang FZ, Fegley B, Chandran B. 2003. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) infection of human fibroblast cells occurs through endocytosis. J Virol 77: 7978-7990. http://dx.doi.org/10.1128/JVI.77.14.7978-7990.2003.
47. Raghu H, Sharma-Walia N, Veettil MV, Sadagopan S, Chandran B. 2009. Kaposi's sarcoma-associated herpesvirus utilizes an actin polymerization- dependent macropinocytic pathway to enter human dermal microvascular endothelial and human umbilical vein endothelial cells. J Virol 83:4895-4911. http://dx.doi.org/10.1128/JVI.02498-08.
48. Ye FC, Blackbourn DJ, Mengel M, Xie JP, Qian LW, Greene W, Yeh IT, Graham D, Gao SJ. 2007. Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J Virol 81:3980-3991. http://dx.doi.org/10.1128/JVI.02089-06.
49. Galinanes M, Bullough D, Mullane KM, Hearse DJ. 1992. Sustained protection by acadesine against ischemia- and reperfusion-induced injury. Studies in the transplanted rat heart. Circulation 86:589-597.
50. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. 2012. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 122:253-270. http://dx.doi.org/10.1042/CS20110386.
51. Dasgupta B, Chhipa RR. 2016. Evolving lessons on the complex role of AMPK in normal physiology and cancer. Trends Pharmacol Sci 37:192- 206. http://dx.doi.org/10.1016/j.tips.2015.11.007.
52. Cazzaniga M, Bonanni B. 2015. Relationship between metabolic reprogramming and mitochondrial activity in cancer cells. Understanding the anticancer effect of metformin and its clinical implications. Anticancer Res 35:5789-5796.
53. Blagosklonny MV. 2011. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget 2:1352-1367. http://dx.doi.org /10.18632/oncotarget.432.
54. Xu J, Ji J, Yan XH. 2012. Cross-talk between AMPK and mTOR in regulating energy balance. Crit Rev Food Sci Nutr 52:373-381. http://dx .doi.org/10.1080/10408398.2010.500245.